ESLA · Estrella Immunopharma, Inc. · Analyst Estimates
$0.47
-0.01 (-1.47%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern. If the Company is unable to obtain adequate financing or generate significant revenue, it may be required to curtail or cease its operations.”View the 10-Q filed Aug 13, 2026
Market Cap
$20.92M
Shares
43.50M
Volume · Oct 2
14.49K
Avg daily vol (3M)
37.45K
Analyst Estimates
Compare analyst forecasts for Estrella Immunopharma, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 04:15 UTC · Publication dates shown per estimate · 16 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.29
|
-0.29
|
-0.29
|
— |
-0.39
|
-0.39
|
-0.39
|
-0.39
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — |
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.32
|
-0.32
|
-0.32
|
— |
-0.32
|
-0.32
|
-0.32
|
-0.32
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — |
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.08
|
-0.08
|
-0.08
|
— |
-0.08
|
0.0
|
-0.08
|
0.0
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — |
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 30 days ago | Average, 60 days ago | Average, 7 days ago | Average, 90 days ago | Estimates lowered, last 30 days | Estimates lowered, last 7 days | Estimates raised, last 30 days | Estimates raised, last 7 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.07
|
-0.07
|
-0.07
|
— |
-0.07
|
0.0
|
-0.07
|
0.0
|
— | — | — | — |
|
EPS
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — |
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0
|
0
|
0
|
— | — | — | — | — | — | — | — | — |
|
Revenue
analysts
Publication date not stated |
— | — | — |
1
|
— | — | — | — | — | — | — | — |